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Abstract
Background: Exercise training has been shown to reduce angina and promote collateral vessel development in
patients with coronary artery disease. However, the mechanism whereby exercise exerts these beneficial effects is
unclear. There has been increasing interest in the use of whole genome peripheral blood gene expression in a
wide range of conditions to attempt to identify both novel mechanisms of disease and transcriptional biomarkers.
This protocol describes a study in which we will assess the effect of a structured exercise programme on
peripheral blood gene expression in patients with stable angina, and correlate this with changes in angina level,
anxiety, depression, and exercise capacity.
Methods/Design: Sixty patients with stable angina will be recruited and randomised 1:1 to exercise training or
conventional care. Patients randomised to exercise training will attend an exercise physiology laboratory up to
three times weekly for supervised aerobic interval training sessions of one hour in total duration. Patients will
undergo assessments of angina, anxiety, depression, and peripheral blood gene expression at baseline, after six and
twelve weeks of training, and twelve weeks after formal exercise training ceases.
Discussion: This study will provide comprehensive data on the effect of exercise training on peripheral blood
gene expression in patients with angina. By correlating this with improvement in angina status we will identify
candidate peripheral blood transcriptional markers predictive of improvements in angina level in response to
exercise training.
Trial Registration: Clinicaltrials.gov identifier: NCT01147952
Background
Regular exercise protects against cardiovascular disease
[1] and has beneficial effects on coronary perfusion and
ventricular function in patients with established coronary
artery disease [2]. However, the exact mechanism
whereby exercise training exerts these effects is unclear.
Meta-analyses have concluded that exercise based cardiac
rehabilitation reduces cardiac mortality in patients with
coronary artery disease (prior myocardial infarction,
angina, bypass grafting or angioplasty) by 26%-31% [3,4].
Although exercise favourably influences serum lipids and
blood pressure, the biological pathway whereby it pro-
tects against cardiovascular death remains unclear,
though there is substantial evidence that exercise
improves myocardial oxygenation. Exercise-induced
improvement in myocardial perfusion has been demon-
strated in a number of studies [2,5] suggesting exercise
training increases absolute myocardial blood flow, rather
than by altering myocardial efficiency. Exercise training
has also been shown to improve coronary artery endothe-
lial function (even after only 4 weeks training) [6].
Some of the favourable effects of exercise appear to be
mediated by improvement in coronary collateral artery
recruitment. Exercise training improves collateral vessel
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function, even in arteries with no coronary stenosis [7].
This is in keeping with epidemiologic evidence that in
patients with coronary artery disease, collateral function
is better in more active individuals [8]. Since better col-
lateral vessel function is associated with improved survi-
val [9], this is a plausible mechanism for the survival
benefit seen with exercise. In keeping with real increases
in myocardial perfusion, in one study exercise training
has been shown to be better at improving angina than
percutaneous coronary intervention [5].
Microarrays enable measurement of expression of
almost all human genes in a small clinical sample simul-
taneously. This powerful technique has been widely
applied in cancer, where the relevant tissue is usually
easily available either through biopsy, or surgical removal.
Application of such techniques is more difficult with
heart disease, since the primarily affected organs (the
heart itself or its supplying coronary arteries) cannot
easily be sampled. However, white blood cells (leuko-
cytes) play a major role in both the development of cor-
onary artery disease [10], in development of collateral
vessels [11] and peripheral blood is easily obtainable.
Thus, the gene expression of peripheral blood (which
reflects gene expression in leukocytes) may be informa-
tive in patients with or at risk of cardiovascular disease.
Previous studies have demonstrated the utility of mea-
suring gene expression in peripheral blood or isolated
cell types from peripheral blood in patients with cardio-
vascular disease. These studies found that gene expres-
sion in either unsorted peripheral blood [12] or isolated
mononuclear cells [13] predicted the presence of coron-
ary artery disease on coronary angiography. Interest-
ingly, gene expression in peripheral unsorted blood
accurately reflects expression of the same genes in
atherosclerotic arteries [12]. These observations support
the validity of peripheral blood as a surrogate of arterial
gene expression. This utility exists either because infil-
trating leukocytes contribute to arterial gene expression
signatures, or pro-atherosclerotic influences alter both
arterial and leukocyte gene expression in a similar
fashion.
In keeping with the central role of circulating leuko-
cytes (particularly monocytes) in collateral vessel devel-
opment, microarray profiling of circulating monocytes is
able to distinguish between patients with good com-
pared with poor coronary collateral vessels [14,15].
One small previous study assessed the effect of exer-
cise training on peripheral blood gene expression [16].
Five patients with metabolic syndrome exercised for 16
weeks, and significant differences in gene expression
were detected in 11 biologic processes. No control
group was used but this study does prove that exercise
induces measurable changes in gene expression even in
a small number of patients.
This study will determine the effect of exercise train-
ing on peripheral blood gene expression in patients
with stable angina and correlate these changes with
improvement in angina status and exercise capacity as a
surrogate of myocardial perfusion. In addition, since
anxiety and depression are highly prevalent among
patients with coronary artery disease and exercise train-
ing has been suggested to improve this, [17] we will
monitor the effect of our intervention on anxiety and
depression.
Methods/Design
Study aims
The purpose of this original research is to characterise
the effect of exercise training on angina status, anxiety,
depression and the peripheral blood transcriptome, in
patients with stable angina and coronary artery disease.
Gene expression outcomes aim to provide an insight
into the mechanism of the beneficial effects of exercise
training in coronary artery disease and on collateral
blood vessel development which might in turn provide
evidence as to the impact upon cardiac morbidity in
these patients.
Study design & setting
This is a prospective randomised control comparison
study. After completion of a baseline assessment, parti-
cipants will be randomly assigned to either a structured
exercise or a usual care control group. Patients will be
randomised by an independent researcher via code
numbers using nQuery software (nQuery Advisor 6.01,
Statistical Solutions, USA). The randomisation sequence
will not be not disclosed to the researcher responsible
for the day-to-day running of the trial until patients
have completed baseline assessments. It is not possible
to blind participants or investigators to treatment alloca-
tion, but data collected will be blinded prior to analysis
to eliminate bias. This research will be conducted in the
Clinical Research Facility (CRF) at the Northern General
Hospital, Sheffield, UK and the Centre for Sport and
Exercise Science at Sheffield Hallam University, UK.
The researchers involved are experienced clinicians and
scientists. Ethical approval was obtained for this study
through Bradford Research Ethics Committee.
Patients
Patients with stable angina will be identified from cardi-
ology clinics at Sheffield Teaching Hospitals NHS Foun-
dation Trust, UK. Written, informed consent will be
obtained from each potential volunteer before baseline
assessment.
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Inclusion Criteria
1) Class I to III angina pectoris (classified according to
the Canadian Cardiovascular Society [CCS]) with docu-
mented myocardial ischemia or coronary artery disease
on angiography.
2) Ability to read and speak English to a level allowing
satisfactory completion of written questionnaires and to
understand instruction during the exercise programme.
3) Age 30-80 years of either sex.
Exclusion Criteria
1) Acute coronary syndromes or recent myocardial
infarction (< 2 months).
2) Left main coronary artery stenosis > 25% or high-
grade proximal left anterior descending artery stenosis.
3) Known reduced left ventricular function (ejection
fraction < 40%).
4) Significant valvular heart disease.
5) Insulin-dependent diabetes mellitus.
6) Occupational, orthopedic, and other conditions that
preclude regular exercise.
7) Patients who’s ECG prevents interpretation of an
exercise test (LBBB, RBBB, pacemaker implantation).
8) Patients already performing greater than 30 min
continuous exercise three times weekly (self-reported).
Exercise intervention
Patients randomised to exercise training will attend an
Exercise Science facility based at Sheffield Hallam
University. This facility has a range of aerobic exercise
equipment, including cycle ergometers, treadmills and
cross-trainers. The intervention will comprise sessions of
aerobic exercise training for 12 weeks total, up to three
times weekly. An interval training regimen will be used,
incorporating three minutes of exercise followed by one
minute active recovery for 30 minutes total. Heart rate
will be monitored throughout; ensuring patients do not
exceed 85% of predicted maximum heart rate or 10 b.m-1
below the angina threshold [1]. Individuals who were tak-
ing medication that alters maximum heart rate (e.g. beta
blockers) will have their exercise intensity monitored
using the Borg Ratings of Perceived Exertion [RPE] scale
[18]. Exercise intensity in this instance will be set at that
point just below the onset of angina. Each exercise ses-
sion will be preceded by 10-15 minutes of light intensity/
gentle mobility exercise and followed by a 10-15 minute
period of cool-down activities. If angina is provoked dur-
ing an interval, exercise will halt until angina subsides,
either with rest or GTN treatment. If angina continues
longer than 5 min the principal investigator or another
clinically qualified investigator will be contacted to assess
the patient. Once angina has subsided, blood pressure
will be checked, and the intervals will restart at a heart
rate 10 b.m-1 below the level which caused the angina
symptoms. Subsequent sessions may exceed this level
of intensity if the angina threshold is found to have
increased (due to exercise training adaptation or altera-
tion of medication).
Hence, each supervised exercise session will last 50-60
minutes in total and patients will be encouraged to
attend as many sessions as possible up to three times
weekly over the 13 week period. Exercise frequency,
intensity, duration and modality, as well as rate of pro-
gression, will be logged. After completing the first six
weeks, participants will have a week break in training
(during which visit 3 takes place), so that acute gene
expression changes in response to exercise do not con-
found the analysis.
Outcome measures
Outcome measures will be performed at CVBRU at base-
line, midpoint (week 7), endpoint (week 14), and 6 month
follow up. At assessment visits patients will have fasted for
at least 12 h. On arrival, the following blood tests will be
obtained; full blood count (FBC), fasting glucose (FG),
fasting lipids (Lip), and peripheral blood RNA (RNA). The
patients will then be offered a light meal. They will com-
plete two questionnaires: The Seattle Angina question-
naire (SAQ), and the Beck Depression/Anxiety Inventory
(BDI). The questionnaires are well established, widely used
and well validated tools for assessing these outcomes
[19-21]. In addition a full drug history will be obtained
(DH). Height and weight will also be recorded (H&W).
Following completion of these questionnaires, an exercise
tolerance test will be performed (ETT) to give an indica-
tion or aerobic exercise tolerance and assess angina
threshold. RNA samples (stored in a HTA licensed Biore-
pository) will be extracted and used to bind to Affymetrix
Human Genome HU133 microarrays to assess whole gen-
ome peripheral blood gene expression. See Figure 1 for
study flow diagram.
Sample size calculation
As our primary outcome measure is gene expression in
whole blood, a priori sample size calculations are not
possible. Based on the pilot study guidelines of [22], we
will recruit 30 volunteers for each group, making a total
sample size of 60. The results of this pilot will provide
information on recruitment, compliance and attrition,
and will identify logistical constraints that might limit
the number of potential recruits. Variability data for the
outcome measures and estimates of the treatment effect
could be used to inform design a subsequent larger-
scale randomised controlled trial, if post hoc analysis
reveals this initial study to be underpowered.
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Statistical analysis
Outcomes will be compared at each assessment point
using a mixed-design factorial ANOVA. Where any sig-
nificant difference existed at baseline between groups,
ANCOVA procedures will be implemented, with base-
line values used as the covariate [23]. Statistical signifi-
cance will be set at p < 0.05. Bivariate relationships
between exercise tolerance and other outcome variables
will be evaluated using Pearson’s correlation analysis.
Data will be analysed using SPSS (SPSS U.K. Ltd, Wok-
ing U.K.). The data will be analysed on an intention to
treat basis with all analyses including missing data by
imputing change across time to be zero. Parametric data
will be presented as mean differences of change scores
Figure 1 Flow diagram indicating participant’s involvement throughout the course of the study.
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between time points, with 95% confidence intervals and
effect sizes (calculated as Cohen’s d i.e. mean of the
treatment effect divided by the standard deviation of the
controls). Gene expression data will be analysed using
our previously published probabilistic method for analy-
sis of microarray data that improves probe level sensitiv-
ity [24-26].
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